Page last updated: 2024-08-21

thiazoles and Myeloproliferative Disorders

thiazoles has been researched along with Myeloproliferative Disorders in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (83.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Bledsoe, S; Borthakur, GM; Bose, P; Bueso-Ramos, CE; Carter, BZ; Cortes, J; Daver, NG; DiNardo, CD; Estrov, ZE; Garcia-Manero, G; Jabbour, E; Jain, N; Kadia, TM; Konopleva, MY; Mak, PY; Masarova, L; Ohanian, M; Pemmaraju, N; Pierce, S; Popat, U; Qiao, W; Verstovsek, S; Wang, X; Zhou, L1
Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D1
Dagger, SA; Duyvestyn, JM; Langdon, WY; Morse, HC; Orandle, M; Taylor, SJ; Thien, CB1
Cortes, JE; Huh, Y; Kanagal-Shamanna, R; Kantarjian, HM; Lin, P; Loghavi, S; Luthra, R; Medeiros, LJ; Mehrotra, M; Patel, KP; Pemmaraju, N; Verstovsek, S1
Amrein, PC1
Fukushima, N; Ichinohe, T; Kimura, S1

Reviews

2 review(s) available for thiazoles and Myeloproliferative Disorders

ArticleYear
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:5

    Topics: Dasatinib; Hematologic Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; Protein Kinase Inhibitors; Pyrimidines; Thiazoles

2011
[Myeloproliferative neoplasms (including chronic myeloid leukemia)].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:1

    Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha; Thiazoles

2012

Trials

1 trial(s) available for thiazoles and Myeloproliferative Disorders

ArticleYear
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.
    Blood advances, 2021, 08-24, Volume: 5, Issue:16

    Topics: Apoptosis; Humans; Myeloproliferative Disorders; Primary Myelofibrosis; Thiazoles

2021

Other Studies

3 other study(ies) available for thiazoles and Myeloproliferative Disorders

ArticleYear
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
    British journal of haematology, 2013, Volume: 161, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured

2013
Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.
    PloS one, 2014, Volume: 9, Issue:4

    Topics: Animals; B-Lymphocytes; Bone Marrow Cells; Cell Lineage; Dasatinib; Dose-Response Relationship, Drug; Germinal Center; Hematopoietic Stem Cells; Humans; Lymphocyte Count; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Myeloproliferative Disorders; Neutrophils; Phosphorylation; Phosphotyrosine; Precursor Cells, B-Lymphoid; Proto-Oncogene Proteins c-cbl; Pyrimidines; RING Finger Domains; src-Family Kinases; Thiazoles

2014
Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
    Blood, 2015, May-21, Volume: 125, Issue:21

    Topics: Aged; Antineoplastic Agents; Calreticulin; Dasatinib; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Male; Myeloproliferative Disorders; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles

2015